23 citations
,
January 2016 in “Frontiers in immunology” Using low-dose IL-2 to increase regulatory T cells might be a safe way to treat type 1 diabetes without severe side effects.
July 2025 in “Journal of Investigative Dermatology” Three molecular subtypes of advanced skin T-cell lymphoma were identified, with potential biomarkers for predicting treatment response and disease progression.
4 citations
,
October 2024 in “Experimental Dermatology” CD8A and FOXD2-AS1 may be key for diagnosing and treating alopecia areata.
November 2025 in “Journal of Investigative Dermatology” PCFCL may have unrecognized subtypes and needs more research.
1 citations
,
November 2002 in “Journal of dermatology” The antibody created from BCC tissues reacts similarly to both BCC and hair follicles, suggesting BCC may come from hair follicle cells.
July 2026 in “Journal of Investigative Dermatology”
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
August 2017 in “Journal of Investigative Dermatology” Activin increases skin tumor formation, skin Tregs help hair growth, lymph-node removal doesn't improve melanoma survival, cells can revert to stem cells in wound healing, and skin bacteria produce peptides that may treat infections.
48 citations
,
January 2024 in “Immune Network” IL-15 is key for T cell function and could help improve treatments for immune-related diseases.
Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.
February 2024 in “bioRxiv (Cold Spring Harbor Laboratory)” Activating TLR9 helps heal large wounds and regrow hair by involving a specific type of immune cell.
32 citations
,
May 2012 in “PloS one” Thymic transplantation normalized some T-cells but not others, maintaining immune function.
105 citations
,
October 2018 in “Nature” A small group of slow-growing cells causes basal cell carcinoma to return after treatment.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
10 citations
,
November 2023 in “Science Immunology” Super-enhancers control CD25 expression in specific cell types, affecting immune function.
May 2018 in “The journal of immunology/The Journal of immunology” Mutations in the FOXN1 gene cause severe immune issues but don't affect hair and nails.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” ZNF750 and MPZL3 are important in causing seborrheic dermatitis.
2 citations
,
February 2025 in “Free Radical Biology and Medicine” Blocking S100A8 can reduce chemotherapy-induced hair loss.
14 citations
,
February 2003 in “Journal of the American Academy of Dermatology” Folliculotropic mycosis fungoides can affect the central nervous system in advanced stages.
32 citations
,
January 2012 in “Clinical & Developmental Immunology” Targeting CD200 could be a new treatment for rheumatoid arthritis.
May 2024 in “Archives of Dermatological Research” TAT-GILZ peptide promotes hair growth by boosting stem cell activity.
60 citations
,
December 1988 in “Journal of Biochemical Toxicology” TCDD reduces EGF receptors in the liver, affecting growth and development.
July 2026 in “British Journal of Dermatology” Soluble CD83 can treat alopecia areata by activating immune cells.
6 citations
,
May 1986 in “Cancer Chemotherapy and Pharmacology” The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
24 citations
,
December 2013 in “Archives of Dermatological Research”
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Immune cells and plasma proteins are linked to hair loss, suggesting new treatment options.
September 2016 in “Journal of Dermatological Science” Plasmacytoid dendritic cells, which overproduce IFN-α, may play a crucial role in starting alopecia areata, an autoimmune disease causing hair loss.
July 2022 in “Journal of Investigative Dermatology” Deleting the MAD2L1 gene is tolerated in certain mouse cancer models.
2 citations
,
May 2024 in “Immunity” Stem cells help control the immune response to improve wound healing.